Skip to main content
Eligibility
for people ages 18 years and up
Location
at San Francisco, California and other locations
Dates
study started
estimated completion:
Principal Investigator

Description

Summary

This study is designed to assess the usefulness of 18F-AV-1451 in Positron Emission Tomography imaging for subjects diagnosed with Frontotemporal Dementia.

Official Title

18F-AV-1451 PET Imaging in Subjects With Frontotemporal Dementia

Keywords

Frontotemporal Dementia

Eligibility

You can join if…

Open to people ages 18 years and up

  • Have provided informed consent or have a legally authorized (LAR) provide consent for study procedures
  • Have had volumetric brain MRI obtained in site's companion protocol within one year of enrollment
  • Can tolerate PET scan procedures

You CAN'T join if...

  • Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances that pose potential safety risk
  • Have history of risk factors for Torsades de Pointes (TdP) or taking medication known to cause QT prolongation
  • Have history of drug or alcohol dependence within the last year
  • Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception
  • Have history of relevant severe drug allergy or hypersensitivity
  • Have received an investigational medication under FDA IND protocol within 30 days of planned imaging session
  • Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging session
  • Possess PET scan evidence of amyloid deposition
  • Determined by the investigator to be unsuitable for this type of study

Locations

  • Movement Disorder Center, UCSD not yet accepting patients
    La Jolla, California, 92037, United States
  • UT Southwestern Medical Center not yet accepting patients
    Dallas, Texas, 75390, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Avid Radiopharmaceuticals
ID
NCT03040713
Phase
Phase 1
Lead Scientist
Gil Rabinovici
Study Type
Interventional
Last Updated
May 1, 2017
I'm interested in this study!